Ruben A. Mesa, M.D.

Ruben Mesa, M.D., obtained his undergraduate work in Nuclear Engineering and Physiology from the University of Illinois in Champaign, Urbana. At Mayo Clinic, he obtained both his medical degree and subsequent training in Internal Medicine and Hematology and Medical Oncology. His scholarship has focused on advancing the understanding and therapy of the chronic myeloproliferative disorders.

In these disorders, he has been very active in evaluating novel therapeutics, implementing clinical trials, working with quality of life studies, and very actively involved with national patient groups. He has been principal investigator or co-principal investigator in 40 clinical trials for patients with myeloproliferative neoplasms (MPN) or other myeloid disorders. He has authored over 300 publications along these latter themes.

Dr. Mesa is committed to improving the therapy and quality of life in MPN patients. He has lectured both nationally and internationally on these disorders, and is an active part of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), and the NCI Funded MPD Research Consortium. He currently receives funding from the MPN Research Foundation for projects with the MPN-Quality of Life Study Group for MPN patient projects.

He founded the biennial Mayo Clinic Living With a Blood Disease Symposium for patients afflicted with hematologic diseases. He currently sits on the editorial board of the journal Blood, and several other key journals.

At Mayo Clinic in Arizona, he is Professor of Medicine, Chair, Division of Hematology & Medical Oncology; and Director of the Acute and Chronic Leukemias Program, Division of Hematology-Oncology.

Currently, Dr. Mesa has active clinical trial programs for myelofibrosis, myeloproliferative disorders, myelodysplastic syndromes and acute myeloid leukemia. He is a co-principal investigator on the international MPD-RC Trials of Pegasys vs. Hydroxyurea in high risk Essential thrombocythemia and Polycythemia Vera. He is involved in a variety of efforts to validate instruments of patient reported outcomes in clinical trials nationally and internationally.